Advertisement
In this report, entitled "MedPredict Thought Leader Insight & Analysis:Anxiety & Depression Q3 2008," a panel of physician experts from North Americaand Europe discuss the strengths and weaknesses of a variety of branded andnear-market antidepressants and anxiolytics.
Advertisement
"In our last report we highlighted three key unmet needs -- higher coreefficacy, more durable remissions and lower side effects," said Dr. JefferyBerk, MedPredict's president and one of the authors of the report. "This newreport identifies the characteristics that next-generation therapeutics willneed to go beyond those benefits and deliver enhanced cognition, reducedanhedonia, and relief from pain and fatigue." Some of the questions addressedby MedPredict's panel:
-- How will FDA's approval of Lilly's Cymbalta for neuropathic diabeticpain and fibromyalgia impact its use in depression? How important is a painindication in treatment of depression?
-- In this challenging regulatory and economic environment, what will newtherapeutics need to demonstrate to displace current usage of SSRIs, SRNIs andgeneric antidepressants? How should these studies be designed?
-- How do thought leaders view the strengths and weaknesses of Lilly'sCymbalta vs. Wyeth's Pristiq?
-- What are the differences in prescribing trends among psychiatristscompared with primary care physicians?
-- Which of the new molecules and mechanisms in development are mostpromising? The panel covers triple reuptake inhibitors, antipsychotics,MAOIs, Beta-3 agonists, nicotinic acetylcholine receptor agonists,NMDA/glutamatergics, GABA, CRH and more.
Companies/Partnerships discussed include: Abbott, AstraZeneca,Bristol-Myers Squibb, Forest/Lundbeck, Forest/Cypress/Pierre Fabre, Lilly,Lilly/Boehringer Ingelheim, Lundbeck/Takeda, Merck-Serono, Ono,Novartis/Servier, Pfizer, Sanofi-Aventis, Sepracor, Targacept/AstraZeneca,Wyeth, and others.
This report can be purchased by contacting MedPredict.
About MedPredict
MedPredict (http://www.medpredict.com) maintains a proprietary database ofover 1,000 global physician thought leaders, including 40+ specialties in 30+therapeutic categories. Based on primary interviews with these thoughtleaders, MedPredict publishes periodic reports in each category to keepclients up-to-date on emerging trends and competitive activity. The reportsinclude thought leader reactions to recent publications and medicalconferences, as well as clinical, regulatory and marketing activity.
SOURCE MedPredict
